Certara Acquires Artificial Intelligence Company That Delivers Predictions to Accelerate Scientific Innovation
Certara, Inc. recently announced it has acquired Vyasa Analytics, LLC. Vyasa provides scalable deep-learning software that allows life sciences organizations to perform predictions and answer complex questions across structured and unstructured bio-medical information. The acquisition will elevate Certara’s software by bringing state-of-the-art artificial intelligence (AI) capabilities to its end-to-end platform.
“We are pleased to announce the acquisition of Vyasa, a cutting-edge company that will enhance existing Certara software platforms and further expand our capabilities across our product portfolios,” said William F. Feehery, Chief Executive Officer of Certara. “By incorporating AI into our suite of products, we are building capabilities that will continue to expand our leadership for biosimulation use cases in drug research and development.”
Formed in 2017, Vyasa software provides a novel AI-powered platform for organizations to integrate and analyze content across their entire enterprise data landscape. Vyasa’s leading product, LAYAR, a flexible and modular data fabric that evaluates quantitative data, text, and images, offers AI capabilities to support decisions in all phases of drug development.
Certara accelerates medicines using proprietary biosimulation software, technology, and services to transform traditional drug discovery and development. Its clients include more than 2,000 biopharmaceutical companies, academic institutions, and regulatory agencies across 62 countries.
Total Page Views: 657
